APDA Announces Two New Centers for Advanced Research

Posted on by Phil Franchina

APDA’s Scientific Advisory Board (SAB) recently approved grants for two new APDA...see more Centers for Advanced Research: the Mayo Clinic in Jacksonville, FL, and The Brigham and Women’s Hospital in Boston, MA. These Centers support large PD research programs and facilitate research which is at the forefront of investigation into the cause, treatment and ultimately cure for PD.

Read More

The American Parkinson Disease Association Awards More Than $1.7 Million in Cutting-Edge Research Grants

Posted on by Phil Franchina

The American Parkinson Disease Association (APDA)...see more is proud to announce more than $1.7 million in funding to support cutting-edge Parkinson’s disease (PD) research including: a prestigious George C. Cotzias Fellowship, two Post-Doctoral Fellowships, 11 Research Grants, and eight APDA Centers for Advanced Research. The grants are part of our 2018-2019 funding cycle.

Read More

APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other conditions

Posted on by Phil Franchina

APDA-funded Brigham and Women’s Hospital explores the genetic variants associated with Parkinson’s disease and other neuropsychiatric conditions In classic biochemistry,...see more ribonucleic acid (RNA) was thought to be a simple middle man between our genome and our proteins. Recently, however, it has become clear that RNA exists in multiple forms and plays a myriad of roles, including regulating protein production, regulating genome activity, and sensing environment. In fact, only a very small portion of DNA gets transcribed into RNA that creates protein. A much large portion gets transcribed into RNA that has various other functions.

Read More

FDA New Analysis on PD Psychosis Treatment

Posted on by Phil Franchina

On September 20, 2018, the FDA recently released results of a new analysis...see more finding no new or unexpected safety risks associated with Nuplazid. The new analysis was initiated because of concerns raised in the media last spring, and reassures patients that they should continue to take Nuplazid as prescribed by their physician. The FDA report highlights a number of important concepts

Read More